The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
117
Subjects will take up to 80 mg daily for 24 months
Site Reference ID/Investigator# 8315
Lafayette, California, United States
Site Reference ID/Investigator# 8306
Jacksonville, Florida, United States
Site Reference ID/Investigator# 8308
Orlando, Florida, United States
CAARS:Inv
Time frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24
CGI-ADHD-S
Time frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24
CAARS:Self
Time frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24
BRIEF-A
Time frame: Day -1, Month 3, 6, 9, 12, 15, 18, 21, 24
AAQOL
Time frame: Day -1, Month 3, 6, 9, 12, 15, 18, 21, 24
WPAI
Time frame: Day -1, Month 3, 6, 9, 12, 15, 18, 21, 24
FTND
Time frame: Day -1, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site Reference ID/Investigator# 8314
Overland Park, Kansas, United States
Site Reference ID/Investigator# 8307
Farmington Hills, Michigan, United States
Site Reference ID/Investigator# 8318
Troy, Michigan, United States
Site Reference ID/Investigator# 8309
Eugene, Oregon, United States
Site Reference ID/Investigator# 8316
Portland, Oregon, United States
Site Reference ID/Investigator# 8310
Memphis, Tennessee, United States
Site Reference ID/Investigator# 8319
Virginia Beach, Virginia, United States
...and 2 more locations